Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro - PubMed (original) (raw)
Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro
C M Rooney et al. Int J Cancer. 1984.
Abstract
Paired Epstein-Barr (EB) virus-carrying cell lines have been established from Burkitt's lymphoma (BL) patients; one the BL-cell line derived from the malignant cells of the tumour and bearing the relevant chromosomal translocation, the other the diploid lymphoblastoid cell line (LCL) derived from the patient's normal B cells by experimental infection with the virus. Comparative studies have shown that both BL and LCL cells are relatively resistant to fresh NK cells but are more susceptible to in vitro-activated NK cells; individual pairs differ as to whether the BL or LCL cells are more sensitive to such effectors. With most cell pairs studied, the two cell types were equally efficient at inducing NK-cell activation in vitro. When the in vitro stimulation protocol was changed to favour the induction of allo-specific responses, most BL cells were noticeably poorer stimulators than the corresponding LCL although both cell types induced a similar pattern of cytotoxicity; this appeared to be directed against HLA class I allo-antigens and could be inhibited by class I antigen-specific monoclonal antibodies. Most BL target lines, though susceptible to this allo-specific lysis, were significantly less so than the corresponding LCL However, only 1/7 BL-cell lines tested vis-à-vis the LCL gave evidence of a gross reduction in HLA antigen expression and this was immediately apparent from both serological typing and cellular analysis.
Similar articles
- Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma.
Rooney CM, Rickinson AB, Moss DJ, Lenoir GM, Epstein MA. Rooney CM, et al. IARC Sci Publ. 1985;(60):249-64. IARC Sci Publ. 1985. PMID: 2998992 - Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance.
Rooney CM, Rowe M, Wallace LE, Rickinson AB. Rooney CM, et al. Nature. 1985 Oct 17-23;317(6038):629-31. doi: 10.1038/317629a0. Nature. 1985. PMID: 2997615 - Restoration of the LFA-3 adhesion pathway in Burkitt's lymphoma cells using an LFA-3 recombinant vaccinia virus: consequences for T cell recognition.
Griffin H, Rowe M, Murray R, Brooks J, Rickinson A. Griffin H, et al. Eur J Immunol. 1992 Jul;22(7):1741-8. doi: 10.1002/eji.1830220712. Eur J Immunol. 1992. PMID: 1378014 - Cell phenotype dependent expression of MHC class I antigens in Burkitt's lymphoma cell lines.
Masucci MG, Klein E. Masucci MG, et al. Semin Cancer Biol. 1991 Feb;2(1):63-71. Semin Cancer Biol. 1991. PMID: 1655115 Review. - T cell recognition of Epstein-Barr virus associated lymphomas.
Rickinson AB, Murray RJ, Brooks J, Griffin H, Moss DJ, Masucci MG. Rickinson AB, et al. Cancer Surv. 1992;13:53-80. Cancer Surv. 1992. PMID: 1330300 Review.
Cited by
- Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.
Li W, Guo L, Rathi P, Marinova E, Gao X, Wu MF, Liu H, Dotti G, Gottschalk S, Metelitsa LS, Heczey A. Li W, et al. Hum Gene Ther. 2017 May;28(5):437-448. doi: 10.1089/hum.2016.025. Epub 2016 Aug 16. Hum Gene Ther. 2017. PMID: 27530312 Free PMC article. - The EBNA-2 N-Terminal Transactivation Domain Folds into a Dimeric Structure Required for Target Gene Activation.
Friberg A, Thumann S, Hennig J, Zou P, Nössner E, Ling PD, Sattler M, Kempkes B. Friberg A, et al. PLoS Pathog. 2015 May 29;11(5):e1004910. doi: 10.1371/journal.ppat.1004910. eCollection 2015 May. PLoS Pathog. 2015. PMID: 26024477 Free PMC article. - Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.
Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA. Ninomiya S, et al. Blood. 2015 Jun 18;125(25):3905-16. doi: 10.1182/blood-2015-01-621474. Epub 2015 May 4. Blood. 2015. PMID: 25940712 Free PMC article. - Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.
Heczey A, Liu D, Tian G, Courtney AN, Wei J, Marinova E, Gao X, Guo L, Yvon E, Hicks J, Liu H, Dotti G, Metelitsa LS. Heczey A, et al. Blood. 2014 Oct 30;124(18):2824-33. doi: 10.1182/blood-2013-11-541235. Epub 2014 Jul 21. Blood. 2014. PMID: 25049283 Free PMC article. - Epstein-Barr virus and the somatic hypermutation of immunoglobulin genes in Burkitt's lymphoma cells.
Harris RS, Croom-Carter DS, Rickinson AB, Neuberger MS. Harris RS, et al. J Virol. 2001 Nov;75(21):10488-92. doi: 10.1128/JVI.75.21.10488-10492.2001. J Virol. 2001. PMID: 11581418 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials